Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial | Zendy

V. V. Rafalsky | Zendy; Alexander Averyanov | Zendy; B. Ya. Bart | Zendy; E. E. Minina | Zendy; Mikhail Putilovskiy | Zendy; Elena Andrianova | Zendy; O. I. Epstein | Zendy

Open Access

Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial

Author(s) -

V. V. Rafalsky,

Alexander Averyanov,

B. Ya. Bart,

E. E. Minina,

Mikhail Putilovskiy,

Elena Andrianova,

O. I. Epstein

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.09.002

Subject(s) - oseltamivir , medicine , adverse effect , population , randomized controlled trial , incidence (geometry) , immunology , covid-19 , physics , disease , environmental health , infectious disease (medical specialty) , optics

Ergoferon is an antiviral complex drug containing released-active forms of antibodies to interferon gamma, CD4, and histamine. Its efficacy and safety in the treatment of acute respiratory viral infections has been reported previously. The aim of this study was to compare Ergoferon with oseltamivir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research